Company Encyclopedia
View More
name
YONGAN PHARMACEUTICAL
002365.SZ
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scientific research and technical service, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming.
3.157 T
002365.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking153/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.28%D
    • Profit Margin3.19%C
    • Gross Margin19.43%D
  • Growth ScoreC
    • Revenue YoY1.07%C
    • Net Profit YoY715.62%A
    • Total Assets YoY-0.68%D
    • Net Assets YoY-1.26%D
  • Cash ScoreB
    • Cash Flow Margin3137.90%A
    • OCF YoY1.07%C
  • Operating ScoreD
    • Turnover0.35D
  • Debt ScoreA
    • Gearing Ratio10.93%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    YONGAN PHARMACEUTICAL released its performance for the first three quarters, with a net profit attributable to the parent company of 25.4963 million yuan, a year-on-year decrease of 58.78%

    According to the Zhitong Finance APP, YONGAN PHARMACEUTICAL released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 577 million yuan, a year-on-year decrease of 6.72%. The net profit attributable to shareholders of the listed company was 25.4963 million yuan, a year-on-year decrease of 58.78%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 5.1844 million yuan, a year-on-year decrease of 86.17%

    Zhitong·
    SZ
    002365
    +0.25%
    Zhitong·
    SZ
    002365
    +0.25%

    YONGAN PHARMACEUTICAL: Net profit for the third quarter was 13.0005 million yuan, a year-on-year increase of 38.75%

    YONGAN PHARMACEUTICAL announced that its revenue for the third quarter was 210 million yuan, an increase of 8.75% year-on-year; net profit was 13.0005 million yuan, an increase of 38.75% year-on-year. Revenue for the first three quarters was 577 million yuan, a decrease of 6.72% year-on-year; net profit was 25.4963 million yuan, a decrease of 58.78% year-on-year

    Zhitong·
    SZ
    002365
    +0.25%
    Zhitong·
    SZ
    002365
    +0.25%

    YONGAN PHARMACEUTICAL: Plans to acquire minority shareholder equity in its controlling subsidiary for 27 million yuan

    YONGAN PHARMACEUTICAL announced that the company plans to use its own funds of 27 million yuan to acquire a total of 49.20% equity in Ling'an Technology Co., Ltd. held by minority shareholders Zhang Yong, Xia Changpei, and Dai Liang, who are part of its controlling subsidiary in Hubei. This move aims to further strengthen control over Ling'an Technology, accelerate its market layout in the business field, and align with the company's overall strategic planning. After the transaction is completed, Ling'an Technology will become a wholly-owned subsidiary of the company. The source of funds is from its own resources and will not affect the company's normal production and operations

    Zhitong·
    SZ
    002365
    +0.25%
    Zhitong·
    SZ
    002365
    +0.25%

    YONGAN PHARMACEUTICAL: Controlling shareholder reduces holdings by 410,000 shares

    YONGAN PHARMACEUTICAL announced that its controlling shareholder's concerted actor, Huanggang Yongan, reduced its holdings by 410,000 shares through centralized bidding on September 4, 2025, accounting for 0.1391% of the total share capital. After this equity change, the company's controlling shareholders, actual controllers, and their concerted actors collectively hold 73,587,200 shares, accounting for 24.9717%, reaching a multiple of 5%

    Zhitong·
    SZ
    002365
    +0.25%
    Zhitong·
    SZ
    002365
    +0.25%

    YONGAN PHARMACEUTICAL's actual controller Chen Yong lifts the lien

    According to the Zhitong Finance APP, YONGAN PHARMACEUTICAL announced that the company's actual controller and chairman, Mr. Chen Yong, was previously investigated by the Hefeng County Supervisory Committee and was subjected to detention. Recently, the company received a notification from Mr. Chen Yong's family that they received the "Notice of Lifting Detention" issued by the Hefeng County Supervisory Committee, which has lifted the detention measures against Mr. Chen Yong

    Zhitong·
    SZ
    002365
    +0.25%
    Zhitong·
    SZ
    002365
    +0.25%
    © 2025 Longbridge｜Disclaimer